Synthesis and in vitro anti-proliferative activity of racemic trifluoro-Casodex® (Bicalutamide)

Letters in Organic Chemistry

Volumn 2, Issue 5, 2005, Pages 447-449

  Sani, Monica ^a   Viani, Fiorenza ^a   Binda, Mara ^b   Zaffaroni, Nadia ^b   Zanda, Matteo ^a  

^a POLITECNICO DI MILANO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anti androgen; Chromatography; Nucleophilic reagents; Prostate cancer; Trifluoro casodex analogue

Indexed keywords

EID: 33645456701     PISSN: 15701786     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570178054405850     Document Type: Review

References (15)

1. (a) Tucker, H.; Chesterson, G. J. J. Med. Chem. 1988, 31, 885.
2. (b) Cockshott, I. D. Clin. Pharmacokinet. 2004, 43, 855.
3. (c) Baltogiannis, D.; Giannakopoulos, X.; Charalabopouloe, K.; Sofikitis, N. Exp. Oncol. 2004, 26, 185.
4. Morris, J. J.; Hughes, L. R.; Glen, A. T., Taylor, P. J. J. Med. Chem. 1991, 34, 447.
5. Tucker, H.; Crook, J. W.; Chesterson, G. J. J. Med. Chem. 1988, 31, 954.
6. See for example: (a) Yin, D.; He, Y.; Perera, M. A.; Hong, S. S.; Marhefka, C.; Stourman, N.; Kirkovsky, L.; Miller, D. D.; Dalton, J. T. Mol. Pharmacol. 2003, 63, 211.
7. (b) He, Y.; Yin, D.; Perera, M.; Kirkovsky, L.; Stourman, N.; Li, W.; Dalton, J. T.; Miller, D. D. Eur. J. Med. Chem. 2002, 37, 619.
8. James, K. D.; Ekwuribe, N. N. Synthesis 2002, 850.
9. Colin, T.; El Kaïm, L.; Gaultier, L.; Grimaud, L.; Gatay, L.; Michaut, V. Tetrahedron Lett. 2004, 45, 5611.
10. For an overview of trifluoropyruvate chemistry, see: Golubev, A. S.; Kolomiets, A. F.; Fokin, A. V. Russ. Chem. Rev. 1992, 61, 779.
11. (a) Sani, M.; Belotti, D.; Giavazzi, R.; Panzeri, W.; Volonterio, A.; Zanda, M. Tetrahedron Lett. 2004, 45, 1611.
12. (b) Gorecka, A,; Leplawy, M.; Zabrocki, J.; Zwierzak, A. Synthesis 1978, 474.
13. Drabowicz, J.; Oae, S. Synthesis 1977, 404.
14. 2 humidified atmosphere. At the end of treatment, adherent cells were washed with phosphate buffered saline and incubated for an additional 72 h. Cells were then trypsinized and counted in a particle counter (Coulter Counter, Coulter Electronics, Luton, UK). Three independent experiments were carried out, and each experimental sample was run in triplicate. The results were expressed as the percentage of cells in compond 1-treated samples compared to untreated-control samples. In vitro activity of the drug was expressed in terms of concentration able to, inhibit cell proliferation by 50 % (IC50).
15. See for example: Wang, L. G.; Mencher, S. K.; McCarron, J. P.; Ferrari, A. C. Oncol. Rep. 2004, 11, 1325.